/L for three consecutive days. Graft failure was defined as the lack of sustained neutrophil recovery, autologous recovery or repeat transplant. (2) Acute and chronic GvHD, diagnosed according to established criteria. 1, 2 The covariates considered were age at transplant ⩽ 18 years vs 418 years), diagnosis (AML/ALL vs CML/MDS), conditioning regimen (nonmyeloablative vs myeloablative), donor-recipient race (matched vs mismatched if either donor has a different racial background from recipient), cryopreserved total nucleated cell (TNC) and CD34 + cell counts of the single unit or engrafting unit in double CBT, HLA disparity (0-1 mismatch vs 2 mismatch) and transplant type (single CBT vs double CBT). HLA disparity and cell dose were maintained in the model, whereas other variables were selected in a backward stepwise manner with a variable retention criterion of P o 0.20.
The median follow-up of surviving patients was 30 months (3-70 months The cumulative incidence of grade II-IV GvHD was 26.0% (CI 14.0-39.0%), whereas that of chronic GvHD was 22.6% (CI 11.0-34.3%). Univariate logistic regression analysis revealed no relationship between conditioning intensity, donor-recipient race match, cell dose (TNC/CD34 + ), HLA disparity or transplant type (double vs single) with acute or chronic GvHD risk (Table 2) . There was a trend toward a lower risk of acute grade II-IV GvHD in patients receiving grafts with 0-1 HLA mismatched units compared with 2 mismatches, but it did not reach significance. In multivariate analysis, cell dose (TNC, CD34 + ) and HLA disparity were both not associated with grade II-IV acute or chronic GvHD risk.
In this study, cryopreserved CD34 + cell dose of the single CB unit or engrafting unit in double CBT were independent predictors of neutrophil recovery rate. Although previous studies in single CBT demonstrate favorable associations between both cryopreserved and infused CD34 + cell dose and engraftment rate, 3,4 the importance of CD34 + cell dose in double CBT is less clearly defined. [5] [6] [7] Furthermore, most data in double CBT are based on infused cell doses, with only one study showing favorable engraftment with higher cryopreserved CD34 + cell dose of the engrafted unit. 7 Currently, CD34 + cell content is not used to assist in CB unit selection at many transplant centers because measurements are not standardized. However, several recent studies show that post-thaw CD34 + cell measurements are closely correlated to cryopreserved values provided by different banks, 7, 8 which suggest that CD34 + measurements may not be significantly different despite different enumeration methods. On the other hand, we found no influence of higher cryopreserved TNC doses on the rate of neutrophil engraftment, possibly owing to the relatively high TNC dose of the CB units in our series. Another reason may be the wide variability of CD34 + cells (×10 5 ) to TNC (×10 7 ) ratio (0.62 ± 0.89 (s.d.)) among CB units supplied for transplant from the SCBB, which suggests that TNC content may not be a good predictor of graft hematopoietic reconstitution potential.
Our study in a predominantly non-Caucasian population found no significant associations of recipient race or donor-recipient racial match on outcomes in both single and double CBT. Although some studies identified higher GvHD risk in ethnic minorities, 9,10 others have not identified any effect. 11 Differences in outcomes between races may be contributed by more significant minor histocompatibility antigen disparity in minorities, lower socio-economic status, or the inability to find a well-matched appropriately-sized cord unit for transplant. 10, 12 Using our local CB bank, a majority (82%) could identify ⩾ 5/6 HLA-matched grafts, and recipients of different racial backgrounds received grafts that were similar in the extent of HLA matching. There is no data at present to suggest that donor race should be included as a factor in CB unit selection.
Limitations of the current study are the small sample size, retrospective setting and heterogeneity of conditioning regimens and transplant procedures. Importantly, we lacked information regarding relapse or disease status at transplant, which limits the validity of the multivariate analysis for transplant outcomes. Race was reported by the transplant center and may not be reflective of true genetic race.
In summary, we have demonstrated the importance of cryopreserved CD34 + cell dose in engraftment outcomes after unrelated single and double CBT. CD34 + cell content of CB units reported by cord blood banks may be potentially a more relevant cellular content to optimize outcomes. Abbreviations: CI = confidence interval; GvHD = graft-versus-host-disease; N = percentage of patients with acute or chronic GvHD; OR = odds ratio; TNC = total nucleated cell.
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